Amryt and Medison distribution agreement for metreleptin in Canada

Global biopharmaceutical company Amryt has signed a distribution agreement with Medison Pharma Canada to distribute Myalepta (metreleptin) in Canada.

Amryt is a global, commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising novel treatments for rare diseases. Medison is a commercial partner of global biotech companies that provide integrated services for biotech companies looking to enter or expand its presence in Israel, Canada and Central Eastern Europe.

Dr Joe Wiley, CEO of Amryt Pharma, said the announcement “represents continued progress as we grow our commercial assets and expand access to treatment for patients in existing and new territories.  We are also pleased to extend our engagement with Medison and further benefit from their expertise in Canada and other territories.”

Myalept/Myalepta (metreleptin) is approved in the US and EU as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL).

This agreement completes the multi-regional distribution agreements with Medison to distribute Myalept (metreleptin) and Lojuxta (lomitapide) in Israel, and Juxtapid (lomitapide) in Canada.

Image credit: Guillaume Jaillet

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free